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Background. Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) 
have rarely been reported in association with inflammatory bowel diseases 
(IBDs).  
Methods. An ECCO COllaborative Network For Exceptionally Rare case reports 
project (ECCO-CONFER) collecting cases of GEP-NENs diagnosed in patients 
with IBD.  
Results. GEP-NEN was diagnosed in 100 IBD patients [61% female, 55% Crohn's 
disease, median age 48 years (IQR 38-59)]. The most common location was the 
appendix (39%) followed by the colon (22%).  
Comprehensive IBD-related data was available for 50 individuals with a median 
follow-up of 30 months (IQR 11-70) following NEN diagnosis. Median duration 
of IBD at NEN diagnosis was 84 months (IQR 10-151), and in 18% of cases NEN 
and IBD were diagnosed concomitantly. At diagnosis, 20/50 were stage-I 
(T1N0M0), and 28/50 graded G1 (ki67≤2%). 
Incidental diagnosis of NEN and concomitantly with IBD diagnosis were 
associated with an earlier NEN stage (p=0.01 and p = 0.02, respectively). 
Exposure to immunomodulatory or biologic therapy was not associated with 




















in the segment affected by IBD (62% vs. 38%). At the last follow-up data, 47/50 
patients were alive, and only two deaths were related to NEN. 
Conclusions. In the largest case series to date, prognosis of patients with GEP-
NEN and IBD seems favorable. Incidental NEN diagnosis correlates with an 
earlier NEN stage and IBD-related therapies are probably independent of NEN 
stage and grade. The association of GEP-NEN location and the segment 
affected by IBD may suggest a possible role of inflammation in NEN 
tumourigenesis 
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Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel 
diseases (IBDs) whose course may be complicated, among others, by 
occurrence of neoplasia [1,2]. Several types of neoplasia have been reported in 
association with IBD in observational studies. These include malignant 
neoplasia related to chronic inflammation (e.g., colorectal cancer, 
cholangiocarcinoma, anal cancers, small bowel carcinoma) and those 
associated with IBD related treatments (e.g., non-melanoma skin cancer, 
lymphoma, urinary tract cancers, and melanoma) [1].  
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumours 
deriving from the diffuse endocrine system and represent about 1% of all 
digestive malignancies [3]. NENs may occur almost anywhere in the body but 
are most commonly diagnosed in the gastrointestinal tract, the pancreas, and 
the lungs, with gastroenteropancreatic (GEP) tumours representing 70% of all 
NENs [4]. Although NENs were historically considered rare, an increasing 
incidence has been reported worldwide over the last four decades [5]. To date, 
GEP-NENs have rarely been reported in association with IBD. Data are limited 
to case-reports and retrospective cohort studies, mainly based on histological 





















We aimed to describe a series of patients with IBD and GEP-NENs, and to 
delineate the association between IBD, GEP-NEN features, and patient 
outcomes.  
Materials and Methods 
This was a retrospective observational multicenter study that collected cases 
across the world through the CONFER [COllaborative Network For 
Exceptionally Rare case reports] project [12] and supported by the European 
Crohn’s and Colitis Organisation [ECCO]. The CONFER proje t was initiated by 
ECCO in order to specifically identify and report rare IBD disease associations, 
which are otherwise seldom reported due to their exceptional rarity. Briefly, 
the CONFER methodology comprises selecting a topic submitted by ECCO 
members and is worthy of investigation. The steering committee of CONFER 
chooses the topic, and ECCO launches a call to identify similar cases 
encountered by IBD physicians worldwide. The call to physicians is made 
through announcements in the ECCO annual congress and in national IBD 
meetings across Europe and during international IBD meetings. In addition, the 
call for similar cases is disseminated by direct emails to all ECCO members and 
affiliated physicians, on the ECCO website, and through the ECCO eNews.  
All adult IBD patients [age >16 years] with a diagnosis of GEP-NEN, according to 




















course of the disease, were eligible for inclusion in this study. Data were 
collected using a standardised case report form, which was divided into three 
domains: 1) patient characteristics, including demographic data, past medical 
history, and IBD-related data; 2) GEP-NEN related data including primary 
tumour site, stage, grade according to ki-67 proliferative index or mitotic 
count, immunostaining pattern, and functioning syndrome; 3)  GEP-NEN and 
IBD-related outcomes. Early stage was defined as absence of lymph node or 
distant metastasis. 
When the NEN was diagnosed after IBD diagnosis, IBD duration was calculated 
from IBD diagnosis until NEN diagnosis. In all cases, follow-up period was 
calculated from NEN diagnosis until last available visit or death. NENs were 
defined as co-localized with IBD when primary tumour site was found within 
the bowel segment affected by IBD. Patients were categorized as exposed to 
advanced therapy [i.e. immunomodulators (IMM) and/or biologics] before NEN 
diagnosis based on the date of the first prescription and onward. Exposure 
status to IBD-related therapies and in particular to advanced therapies 
(exposed vs non-exposed) was described in different NEN subgroups to explore 




















The data were collected and analysed anonymously and handled according to 
local regulations. Data were analysed for event association with patient and 
IBD-related factors. 
A general Review Board approval is available for this ECCO project on the ECCO 
website. Moreover, each participating center received a local Institutional 
Review Board approval. 
Statistical analysis 
Continuous variables were expressed as mean and standard deviation or 
median and interquartile range (IQR) as needed, and compared using Student’s 
t-test. Categorical variables were expressed as proportions and compared by 
means of the Fisher’s exact test and 95% confidence interval was calculated. A 
p-value less than 0.05 was considered statistically significant. For the statistical 






















One hundred cases of GEP-NENs diagnosed in patients with IBD (61% female, 
55% CD, 41% UC, 4% IBD-U) were collected from 25 referral centres in 10 
different countries (Supplementary Figure 1). The vast majority of cases (97%) 
were reported from academic centres. Of these, 51 cases were previously 
reported within case-series [6] and case-report [11].   
Among the entire cohort, median age at GEP-NEN diagnosis was 48 years (IQR 
38-59). The most common location of the primary tumour site was the 
appendix (39%) followed by the colon (22%), ileum (19%) and rectum (11%) 
(Figure 1).   
GEP-NEN diagnosis was made after a median time of 84 months (IQR 10-151) 
from IBD diagnosis, of whom the majority of patients (56%) received NEN 
diagnosis ≥60 months after diagnosis of IBD. In 18 cases both diagnoses were 
made concomitantly. None of the patients was diagnosed with GEP-NEN prior 
to IBD diagnosis.  
Clinical characteristics of the entire cohort are reported in table 1. 
Comprehensive follow-up data was available for 50 cases and were therefore 




















presented in supplementary table 1. The median follow-up after GEP-NEN 
diagnosis was 30.5 months (IQR 11.2-70) . 
In 36/50 cases GEP-NEN were discovered incidentally either during follow-up 
imaging or endoscopy (25/50) or within surgical specimen (11/50). In 14 of the 
50 cases, the presence of new symptoms led to NEN diagnosis. Notably, none 
of the cases were associated with a functional NEN syndrome. 
GEP-NEN stage and grade 
At diagnosis, 19/50 (38%) of NENs were at stage I while 13/50 (26%) and 3/50 
(6%) were diagnosed at stage III and IV, respectively. Moreover, 28/50 graded 
G1 (proliferation index ≤3 % or mitotic rate below 2 per 2mm2). Complete NEN 
characteristics are reported in Figure 2.  
GEP-NEN therapy 
Majority of patients, 45 (90%) underwent surgery with curative intent. Of 
these, at the end of follow-up, 37 (82%) were disease free, seven (16%) had 
disease progression due to residual or recurrent disease and one (2%) had 
stable disease. Of the remaining five cases that did not undergone surgery, one 
(primary site rectum; G3) was treated with chemotherapy; one (primary site: 
sigmoid; G3 did not receive any treatment due to rapid disease progression 




















treatment and a “wait and see” strategy was adopted; one (primary site: 
pancreatic T1N0M0) was treated with somatostatin analogues alone. 
Features of IBD  
Active IBD at the time of NEN diagnosis defined by clinically, biochemically, or 
endoscopically active disease was documented among 35/50 (70%) of patients. 
No difference between CD and UC patients regarding NEN characteristics 
(tumour grade and stage) and disease course (proportion of patients being 
disease free, having stable disease or with disease progression at the end of 
follow-up) were found in our series. 
A total of 24/50 (48%) patients had been exposed to advanced therapy at the 
time of NEN diagnosis for a median duration of 20.5 months (IQR 9-74). Of 
these 24 patients, four been actively treated with advanced therapy and in all 
of them treatment was discontinued following NEN diagnosis. Of note, there 
was no association between exposure to an advanced therapy and advanced 
NEN stage or grade (p=0.14 and p=0.91, respectively), compared with patients 
not exposure to an advanced therapy.  
Incidental diagnosis of NEN either during follow-up or during surgery as well as 
receiving diagnosis of NEN concomitantly with IBD was significantly associated 




















0.97, respectively). In 31/50 (62%) cases NEN primary site was found within the 
bowel segment affected by IBD compared to 19 cases (38%) whose NEN site 
was not affected. 
Outcome and prognosis 
At the last follow-up date, 47/50 (94%) patients were alive. Of whom, 31/50 
had quiescent IBD, while 16/50 had active IBD. Three deaths occurred, of 
which, two were related to NEN. The first patient, a 71-years-old man suffering 
from extensive UC, had a diagnosis of high grade, poorly differentiated rectal 
NEN (G3, stage T3N0M0) and died 4 months after NEN diagnosis after failing to 
response to neoadjuvant chemotherapy. No data about drug exposure and IBD 
duration were available for this patient. The second patient was a 61-years old 
man with a history of long-standing extensive UC treated with azathioprine for 
7 years, who developed an advanced small cell neuroendocrine carcinoma of 
the sigmoid colon with metastatic liver disease (G3, T4N1M1). Death occurred 





















        GEP-NENs are considered a rare entity but their incidence is increasing 
worldwide [17] and they may represent a clinical challenge given their protean 
behaviour. IBDs are relatively common and GEP-NENs have rarely been 
reported in association with IBD. The current multi-center case-series of GEP-
NEN, the largest to date, in patients with IBD, has demonstrated that cases are 
predominantly diagnosed during the 4th and the 5th decade of life, at median of 
7 years from IBD diagnosis and most commonly within the appendix and along 
the large bowel. Of note, in two thirds of the cases GEP-NEN was diagnosed at 
the bowel segment involved in the underlying IBD. Importantly, we have found 
that more than 70% of GEP-NEN being diagnosed incidentally during IBD 
follow-up and in early stage. Finally, the vast majority of GEP-NEN cases among 
patients with IBD carries a favorable prognosis during a median follow-up of 
over 30 months.   
Compared to sporadic NEN not associated to IBD, both age at NEN 
diagnosis and the primary tumour site seems to be different. In the present 
case series, the median age at NEN diagnosis was 51 years, more than 7 to 10 
years earlier than the age reported in historical cohorts and in population-
based registries [18-21]. The younger age at NEN diagnosis in patients with IBD 




















monitoring involving endoscopic and imaging studies; 2. patients with IBD 
more commonly undergo intestinal surgeries thus incidental findings at a 
younger age group are more likely to occur; 3. Our cohort include 40% 
appendiceal NEN, a subtype that may appear at younger age [22].  
Alternatively, an expedited pathogenesis related to inflammation might have a 
role in the development of GEP-NEN tumourigenesis in patients with IBD.  
Interestingly, an interaction between the neuroendocrine system and the Th17 
pathway in human IBD has been described, possibly supporting this hypothesis 
[23].  Moreover, previous studies demonstrated an inflammation induced 
hyperstimulation of enteroendocrine cells that can result in hyperplasia and 
ultimately neoplastic transformation [24-27]. 
As for anatomic distribution of tumors, we found that the most common 
primary tumour sites were the appendix, the colon, the ileum and the rectum, 
overall accounting for about 90% of all cases. Compared to historical cohorts 
where ileal and rectal NENs account for 40-65% of cases [18-21], in our series 
the most frequent primary tumour sites were appendix and colon, together 
reaching 61%. On one hand, this could reflect a diagnostic bias, due to the high 
prevalence (72%) of incidentally discovered NEN cases, either during follow-up 
procedures for the underlying IBD (i.e., colonoscopy) or on the surgical 




















a peculiarity on NEN associated to IBD. In contrast to our findings, in a 
previously described case-series of four NEN cases identified within 111 CD 
specimens, no correlation was found between areas involved by inflammation 
and NEN [28]. This discrepancy may be explained by the significant larger 
number of patients enrolled in our cohort.  
Generally, prognosis of patients with concomitant GEP-NEN and IBD 
seems favorable and similar with that of NEN in the general population [21, 
29]. In fact, after a median follow-up of 30.5 months, 94% of patients were still 
alive. In a recently published American cohort study of 43,751 patients with 
GEP-NEN, the overall 3-year survival ranged from 98% for localized disease to 
~50% advanced disease with distant metastasis [21]. In our population, the 
aforementioned high prevalence of gastrointestinal primary site, the 
predominant early stage (74% of patients did not present lymph node or 
distant metastases) and the general favorable grading (72% of case had G1 or 
G2) at diagnosis are the clinical factors that most likely contributed to this 
favorable prognosis.  
Noteworthy, we found no cases of functioning NEN in our cohort. This 
finding is lower than the reported functioning syndrome rate in previous 
reports on specific subtypes of GEP-NENs, ranging from 3–13% with NEN of the 




















prevalence of pancreatic and ileal NENs (25% of cases, overall) and the 
generally early stage at diagnosis found in our series may explain this 
peculiarity. 
 We found no association between IBD-related therapies and particularly 
conventional immunomodulatory and or biologic therapies and NEN stage and 
grade at diagnosis. This observation is reassuring and is in line with previous 
data reporting no increased cancer risk among patients with IBD treated with 
biologic therapies [31-33]. However, larger cohorts followed longitudinally for 
longer periods are needed to rule out possible relationship between these 
treatments and GEP-NEN long-term course and prognosis.  
Finally, as expected, incidental NEN diagnosis either during follow-up or 
during surgery was correlated to an earlier stage compared to cases diagnosed 
during investigation of new symptoms. This finding corroborates previous 
study reporting a lower stage and better prognosis for patients with 
incidentally discovered pancreatic NEN [21, 34].   
However, some limitations need to be pointed out in this study mostly 
inherent biases of a retrospective case series design. Data report might be 
subjected to geographical and selection biases. However, the relatively large 
number of cases and the participation of 25 centers from 10 different 




















sample size, definitive conclusions on association between IBD related and 
NEN related factors are limited.  
In conclusion, the largest case series to date that included thorough IBD 
and NEN related data with a longitudinal follow-up, showed that prognosis of 
patients with GEP-NEN and IBD appear largely comparable with that of 
sporadic NEN cases, when compared to historical case series. Incidental GEP-
NEN diagnosis correlates with an earlier NEN stage and IBD related therapies 
do not seem to influence NEN stage and grade. The association between GEP-
NEN location and the segment affected by IBD may suggest a possible role of 
inflammation in NEN tumourigenesis. However, larger observational case-
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Table 1. Clinical characteristics of patients with inflammatory bowel diseases and neuroendocrine neoplasia 
Total patients  n=100 
Age at IBD diagnosis 
Median years (IQR) 
 
39 (29-51) 
Age at NEN diagnosis 
Median years (IQR) 
 
48 (38-59) 




Ethnicity,  n (%) 
White  
Mixed-ethnic group  
Asian  
Black/Caribbean/African  









































































Previous IBD related surgery, n 10 






IQR, interquartile range; A1, >17 years old; A2, 18-40 years old; A3, >40 years old; N/A, not 
available; L1, ileal; L2, colonic; L3, ileocolonic; L4, upper disease; B1, inflammatory; B2, 
stricturing; B3, penetrating; E1, Ulcerative Proctitis; E2, Left Sided Colitis; E3, Pancolitis. 5-
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